Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cresco LabsCRLBF -5.46%29 EV-to-EBITDA is 53.51 as of Sep. 04, 2026. GuruFocus rates CRLBF with a GF Score™ of 29/100 and a GF Value™ of $0.87 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 726 Drug Manufacturers companies, Cresco Labs ranks worse than 88.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cresco Labs's enterprise value is $739.9 Mil.
Cresco Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $13.8 Mil. Therefore, Cresco Labs's EV-to-EBITDA for today is 53.51.
The historical rank and industry rank for Cresco Labs's EV-to-EBITDA or its related term are showing as below:
CRLBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5885.48 Med: -4.83 Max: 714.74
Current: 53.45
During the past 13 years, the highest EV-to-EBITDA of Cresco Labs was 714.74. The lowest was -5885.48. And the median was -4.83.
CRLBF's EV-to-EBITDA is ranked worse than 88.71% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.55
vs CRLBF: 53.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cresco Labs's PE Ratio (TTM) for today is calculated as:
Cresco Labs's share price for today is $0.7412.
Cresco Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cresco Labs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cresco Labs EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cresco Labs's EV-to-EBITDA falls into.
Cresco Labs's current Enterprise Value is $739.9 Mil.
Cresco Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cresco Labs (CRLBF) has a EV-to-EBITDA of 53.51 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cresco Labs. According to the industry distribution chart, Cresco Labs ranks #644 out of 726 companies in the Drug Manufacturers industry, placing it in the top 88.7%.
Is Cresco Labs' EV-to-EBITDA too high?
Cresco Labs' current EV-to-EBITDA is 53.51. The Drug Manufacturers industry median EV-to-EBITDA is 13.55. Cresco Labs' value of 53.51 is 294.9% above this industry median. Based on the distribution chart, Cresco Labs ranks #644 out of 726 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cresco Labs has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #644 out of 726 companies for EV-to-EBITDA. This places Cresco Labs in the lower half of its industry. The industry median EV-to-EBITDA is 13.55. Cresco Labs' value of 53.51 is 294.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.55, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cresco Labs's current EV-to-EBITDA of 53.51 is 294.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cresco Labs. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current EV-to-EBITDA is 53.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (CRLBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.87, compared to a current price of $0.74 — trading 14.8% below its estimated fair value. The current EV-to-EBITDA is 53.51 and 294.9% above the Drug Manufacturers industry median of 13.55. Cresco Labs' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cresco Labs (CRLBF), the current EV-to-EBITDA is 53.51 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cresco Labs (CRLBF) Overvalued in 2026?
Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued.
The current stock price of $0.74 is trading 14.8% below its estimated GF Value™ of $0.87.
GuruFocus considers Cresco Labs to be Modestly Undervalued.
Key valuation signals for CRLBF:
EV-to-EBITDA: 53.51
GF Value™: $0.87 vs. price of $0.74 (14.8% below fair value)
Industry Position: 294.9% above the Drug Manufacturers median (#644 of 726)
No single metric tells the full story. See the CRLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
29GF Score
Get the complete analysis for CRLBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRLBF has been successfully added to your 
